Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma | Synapse
February 25, 2021Open Access
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Compared to PL, HPL was associated with a significantly better treatment response and survival benefits for patients with advanced HCC.